MRI for the Diagnosis of Placenta Accreta Spectrum

Status Recruiting

Clinical Trial Summary

Placenta Accreta Spectrum (PAS) is a disease associated with abnormal placental adhesion and invasion. In recent years, the incidence of PAS has increased significantly, which can cause massive postpartum hemorrhage, hysterectomy,and even maternal mortality. The research team of Peking university third hospital developed the ultrasound rating scale in china at first to conduct preliminary assessment of the PAS risk which can identify the severity of cases. In a basis of ultrasound, plan to explore the MRI for the the investigators diagnosis of PAS according to some specific PAS features, like the the uneven signal intensity , the myometrial discontinuity, and black band on T2 image, and finally established a MRI scoring system of PAS. MRI score system of PAS can reduce the subjective difference of the clinician's visual reading, and assist the clinician to assess the risk of sever PAS further, and conduct perioperative preparation to reduce the risk of maternal morbidity and mortality to achieve a better clinical outcome.

Clinical Trial Description

Placenta Accreta Spectrum (PAS) is a disease associated with abnormal placental adhesion and invasion. In recent years, the incidence of PAS has increased significantly, and the main risk is high hysterectomy rate,massive postpartum hemorrhage, and even maternal mortality in women at childbearing age. The research team of Peking university third hospital developed the ultrasound rating scale in china at first to conduct preliminary assessment of the PAS risk which can identify the severity of cases and guide the junior hospitals to transfer. Peking University third hospital is in the leading position in the preoperative diagnosis of PAS currently.

Magnetic resonance imaging (MRI) has become a common method for preoperative evaluation for sever cases. MRI can provide a map of the placenta and PAS features, like the uterus enlarged significantly, the uneven signal intensity , the myometrial discontinuity, and black band on T2 image. It has a high diagnostic value. At present, only Lim and Ueno reported MRI scoring system for PAS. Due to the small sample size and the limitation of the research methods, a widely applicable rating scale has not been established. MRI score system of PAS can reduce the subjective difference of the clinician's visual reading, and assist the clinician to assess the risk of sever PAS further, and conduct perioperative preparation to reduce the risk of maternal morbidity and mortality and achieve a better clinical outcome. ;

Study Design

Related Conditions & MeSH terms

Placenta Accreta

Clinical Trial Details

NCT number	NCT04151979
Study type	Observational
Source	Peking University Third Hospital
Contact	Lian Chen
Phone	+8613811748746
Email	bysychenlian@126.com
Status	Recruiting
Phase
Start date	January 1, 2015
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04579172` - Conservative Management of Morbidly Adherent Anterior Situated Placenta	N/A
Completed	`NCT04593303` - Internal Iliac Artery Ligation During Management of Placenta Accreta Spectrum	N/A
Recruiting	`NCT03638024` - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Not yet recruiting	`NCT06100640` - Paracervical Pouch in Placenta Accreta Spectrum
Completed	`NCT05979181` - Peripartum Cesarean Hysterectomy for Placenta Percreta
Recruiting	`NCT04609527` - Management of Placenta Accreta Spectrum	Phase 2/Phase 3
Recruiting	`NCT06185894` - The Role of Using Tourniquet in Decreasing Bleeding in Placenta Accreta Spectrum Cases	N/A
Completed	`NCT04573452` - Galectin-3 and Placenta Accreta
Not yet recruiting	`NCT03273569` - PDIUC Protocol for Placental Accreta	N/A
Completed	`NCT03707132` - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Not yet recruiting	`NCT05104177` - Effectivness of Conservative Techniques in Management of PAS
Completed	`NCT02806024` - Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study	Phase 4
Active, not recruiting	`NCT02784886` - Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta	N/A
Recruiting	`NCT05070689` - Placenta Accreta Spectrum Disorders: A. Chohan Continuous Squeezing Suture (ACCSS)	N/A
Completed	`NCT05813743` - Detection of Urinary Bladder Wall Involvement in Abnormally Invasive Placenta (AIP) by 3D Ultrasonography	N/A
Withdrawn	`NCT04003428` - Feasibility of HIFU for Management of Placenta Accreta (HIFU-ACCRETA)	N/A
Completed	`NCT04161521` - Conservative Surgical Novel Technique of Placenta Accreta in Menoufia University Hospital	N/A
Recruiting	`NCT05139498` - Conservative Management for PAS Pilot	N/A
Not yet recruiting	`NCT03530475` - Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler	N/A
Recruiting	`NCT05922397` - Placenta Accreta Spectrum Topographic Classification

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.